Why the study?
The potential effects of COVID-19 vaccines on ACE2 gene expression in individuals with pre-existing cardiac disease remain incompletely understood.
Does COVID-19 vaccination alter ACE2 gene expression in cardiac patients compared with healthy controls?
Population
90 participants (47 healthy controls and 43 patients with confirmed heart disease)
Comparison
Cardiac patients vs healthy controls after COVID-19 vaccination
Design
Comparative observational study
Key result
COVID-19 vaccination was not associated with a statistically significant difference in venous tissue ACE2 mRNA expression between patients with cardiovascular disease and healthy controls.
Authors
Loading...
No ACE2 expression change in vaccinated CVD patients suggests no immediate clinical concern; leaves open prospective studies on tissue-specific effects.
Observational (n=90)
No
Does COVID-19 vaccination alter ACE2 gene expression in cardiac patients compared with healthy controls?
p-value: p=>0.05
COVID-19 vaccination does not appear to significantly alter ACE2 gene expression in venous tissue of patients with cardiovascular disease compared to healthy controls.
Shihab et al. (2026) conducted an observational in Cardiovascular disease (n=90). Cardiovascular disease vs. Healthy controls was evaluated on Normalized ACE2 mRNA expression in venous tissue (p=>0.05). COVID-19 vaccination was not associated with a statistically significant difference in venous tissue ACE2 mRNA expression between patients with cardiovascular disease and healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: